What is the recommended dosing for Megestrol (megestrol acetate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Megestrol Acetate Dosing Recommendations

For cancer-related anorexia/cachexia, megestrol acetate should be dosed at 400-800 mg per day orally, with the FDA-recommended initial dosage being 800 mg/day (20 mL/day) of the oral suspension. 1

Dosing by Indication

Cancer-Related Anorexia/Cachexia

  • Initial dose: 800 mg/day (20 mL/day) of oral suspension 1
  • Effective dose range: 400-800 mg/day 2, 1
  • Clinical trials comparing different dose schedules found that 400 and 800 mg/day were both clinically effective 1
  • Optimal dose appears to be between 480 and 800 mg/day based on comparative trials 2
  • Lower doses (80 mg twice daily) may be considered as a starting dose in some patients, with potential for dose escalation if needed 3

Administration Considerations

  • Oral suspension should be shaken well before using 1
  • Liquid formulation may be less expensive and more bioavailable than tablets 2
  • For twice-daily dosing, administration after meals may be beneficial 3

Evidence Quality and Efficacy

  • Megestrol acetate has been studied in more than 30 randomized clinical trials 2
  • High-level evidence supports its use for appetite stimulation in cancer patients 2
  • Benefits include improved appetite and weight gain, though primarily through increased fat mass rather than lean body mass 2, 4
  • In a meta-analysis of 23 trials with 3,436 cancer patients, megestrol acetate doses of 160-1600 mg/day for 2 weeks to 2 years showed favorable results for appetite and weight gain compared to placebo 2

Potential Adverse Effects

  • Common side effects include edema, thromboembolism, and adrenal insufficiency 2
  • Higher doses are associated with increased risk of death (RR, 1.42), thromboembolic events (RR, 1.84), and edema (RR, 1.36) 2
  • Cortisol suppression is common at higher doses and may be persistent, though clinical symptoms of adrenal insufficiency are rare 5
  • Drug interactions: Megestrol is contraindicated with concomitant use of dofetilide due to risk of QT prolongation 2

Special Populations

Renal Impairment

  • Moderate doses (400 mg/day) have been used safely in hemodialysis patients to improve nutritional status and appetite 6, 4
  • In dialysis patients, 400 mg/day for 16 weeks improved nutritional parameters without major side effects 6

Elderly Patients

  • Doses of 400-800 mg daily have shown improvements in prealbumin levels in elderly patients with poor appetite after hospitalization 5
  • Cortisol suppression is dose-dependent and more common at higher doses (70% at 400 mg, 78% at 800 mg) 5

Clinical Decision Making

  • For patients with advanced cancer and anorexia/cachexia, start with 800 mg/day (FDA recommendation) 1
  • For elderly or frail patients, consider starting at 400 mg/day and titrate based on response 5
  • For patients with renal impairment, 400 mg/day appears to be both effective and well-tolerated 6
  • Monitor for adverse effects, particularly edema and thromboembolic events 2
  • Consider discontinuation if no improvement in appetite is seen after 4-8 weeks of therapy 2

Important Considerations

  • Megestrol acetate increases weight primarily through fat mass, not lean body mass 2, 4
  • The medication should not be used with dofetilide due to drug interactions 2
  • ASCO guidelines recommend megestrol acetate as a pharmaceutical option for management of cancer cachexia 2
  • NCCN Palliative Care guidelines list megestrol acetate (400-800 mg/day) as an appetite stimulant option for patients with anorexia/cachexia 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 1999

Research

Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.